南新制药(688189.SH)：2025年预亏1.2亿元至1.6亿元

Core Viewpoint - Nanjing New Pharmaceutical (688189.SH) expects a significant decline in revenue and net profit for the fiscal year 2025, indicating ongoing financial challenges for the company [1] Financial Performance Summary - The company projects an annual revenue of between 120 million to 150 million yuan for 2025, which represents a decrease of 113.2848 million to 143.2848 million yuan compared to the previous year, translating to a year-on-year decline of 43.03% to 54.42% [1] - After excluding non-core business income and income lacking commercial substance, the expected revenue is between 119.9 million to 149.9 million yuan [1] - The anticipated net profit attributable to the parent company is expected to be a loss of between 160 million to 120 million yuan, which is a reduction in loss of 196.9036 million to 236.9036 million yuan compared to the previous year, reflecting a year-on-year decrease in loss of 55.17% to 66.38% [1] - The projected net profit attributable to the parent company, after excluding non-recurring gains and losses, is expected to be a loss of between 165 million to 125 million yuan, with a reduction in loss of 193.5310 million to 233.5310 million yuan compared to the previous year, indicating a year-on-year decrease in loss of 53.98% to 65.14% [1]